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Abstract
Chronic subdural hematoma (SDH) is commonly seen in the aged population. It is hypothesized to occur due to
damage to the dural border cells, resulting in an inﬂammationeproliferation reaction. Inadequate repair leads to the
formation of an external layer of cells and fragile capillaries, which are vulnerable to damage, contributing to worsening
of the condition. Conventionally, asymptomatic chronic SDH was managed by observation, while symptomatic cases by
surgical evacuation. However, the recurrence rate of chronic SDH after surgical evacuation was high. The middle
meningeal artery (MMA) provides blood supply to the dura mater and feeds the capillaries of the membranes covering
the SDH. MMA embolization blocks blood ﬂow to this system and promotes hematoma resolution. In this manuscript,
we discuss the underlying pathophysiology and current management options for chronic SDH. We also discuss the
existing literature on MMA embolization.
Keywords: Chronic, SDH, MMA, MMA embolization, Endovascular

1. Introduction

C

hronic subdural hematoma (SDH) is characterized by an encapsulated organized blood
collection in the subdural space between the dura
matter and arachnoid matter. An overall increase in
the elderly population has resulted in an increased
incidence of chronic SDH. Over the past ﬁfteen
years, the incidence has roughly doubled from 8.2 to
17.6 cases per 100,000 years.45,38 Apart from age,
other well-established risk factors include male
gender, dependency on antiplatelet or anticoagulant
medication, and chronic alcoholism.1 With an increase in the elderly population and polypharmacy,
along with pervasive usage of imaging technology,
more cases of chronic SDH are being diagnosed
each year. It is predicted that by 2030, there will be
at least 60,000 new cases of chronic SDH every year.2
The diagnosis of chronic SDH can present as a
clinical challenge, with the early stage of the disease usually being insidious, while the later-stage

symptoms can be hard to recognize.47 These may
include gait disturbance and falls (55.5%), mental
deterioration (34.0%), limb weakness (34.0%), acute
confusion (32.1%), headache (17.2%), drowsiness or
coma (9.6%), speech impairment (5.7%), collapse
(1.0%), and seizure (1.0%).23 Motor dysfunction is
observed as tremors or gait disturbances, and
aphasia and paresthesia may also occur. Diseases
like dementia, Alzheimer's disease, Parkinson's
disease, normal pressure hydrocephalus, and other
age-related diseases can disguise the illness, making it an even bigger diagnostic challenge, resulting
in a delayed diagnosis.36 In the later stages of
the disease, patients may develop seizures or
hemiparesis.46
Chronic SDH can have long-term adverse effects
on health. One study showed that the mortality rate
due to chronic SDH was 13%, and at least 20% of
patients required prolonged healthcare assistance.13
While the in-hospital mortality rate of chronic SDH
is low, mortality rates as high as 30% can be seen six
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months to one year after the initial presentation.
This shows that chronic SDH can play a role in
triggering the ‘end of life’ period in the elderly.10

2. Alternate theories of underlying
mechanisms
Traditionally, chronic SDH was believed to be an
accumulation of a low-ﬂow collection of venous
origin in the subdural space, occurring due to a tear
in the bridging veins on their route to the dural
venous sinuses.31 However, several other factors
appear to play a central role. Venous injury would
result in slow, but immediate extravasation of blood
into the subdural space visualized on a head
computerized tomography (CT) scan. In contrast,
clinical observations show normal head CT scan
obtained a few hours after trauma in patients who
developed chronic SDH several weeks or months
later.11 The time frame of venous blood accumulation and symptoms is variable and does not correlate directly with the time of insult. In many cases,
symptoms do not occur within days but usually
develop after a period of 4e7 weeks following
trauma.14 On CT scans, chronic SDH is often viewed
as a mass of mixed density with chronic and acute
changes. It is inconsistent with venous bleeds that
show up as an area of fresh hemorrhage8 (Fig. 1).
Over the last few years, various pathophysiological mechanisms have been suggested. Chronic
SDH is now considered a continuous process consisting of both inﬂammation and proliferation. In a
detailed review, Edlmann et al. described the
different steps involved in the pathogenesis of
chronic SDH.11 It has been deliberated that chronic
SDH occurs not due to venous injury but due to
injury to a highly specialized group of cells called
the dural border cells. The dural border lies on the
inner side of the dura mater. The dural border is
made of special connective tissue cells. These cells,
which when healthy, are capable of laying down
ﬁbro-cellular connective tissue. When damaged,
they cause an inﬂammatory reaction, leading to
ﬁbrogenesis and angiogenesis.29
If inﬂammation fails to repair the dural border
cells, a new dural layer forms, comprising of two
layers. Of the two layers, the external layer is
consistent with the dura and plays a role in the inﬂammatory process due to the presence of inﬂammatory cells, and a large number of fragile newly
formed capillaries. The internal layer, next to the
arachnoid mater, is not involved in inﬂammation.4
Injury to the new, fragile capillaries leads to
bleeding and expansion of the chronic SDH. The
bleeding is aggravated by a hyper-ﬁbrinolytic state

arising from raised levels of tissue plasminogen
activator (released from the external membrane)
and thrombomodulin (released from injured
vessel walls).34,20 The process of inﬂammation
and bleeding continues to feed the hematoma until
the hematoma is detected and appropriately
managed.17

3. Reevaluating the standard approaches to
management
The standard approach depends on the patient's
symptoms and the size and mass effect of hematoma. Monitoring without intervention is recommended in asymptomatic cases. If the hematoma is
small, spontaneous resolution may occur. Kim et al.
studied 16 patients and showed that asymptomatic
chronic SDH has a resolution rate of 81.3%.22
However, even if asymptomatic, the hematoma size
plays a role in treatment decisions: hematomas less
than 10 mm in diameter and causing a midline shift
of less than 5 mm, may be expected to resolve with
conservative treatment.12 Larger hematomas
become symptomatic with time.
In symptomatic patients, decompression of the
hematoma, usually by surgical evacuation, is recommended (Fig. 1). Different surgical approaches
are available. The twist drill craniotomy can be
performed at the bedside, and it consists of small
burr holes (<10 mm). When the hematoma is large
or a bedside approach is not feasible, the burr hole
craniotomy is preferred. It consists of bigger burr
holes (>10 mm) and is preferred by most surgeons.
Craniotomy, which involves a larger bone window
(>30 mm), is done in cases with an acute component, or in recurrent cases when multiple membranes prevent drainage through a simple burr hole.
A subdural drainage system is usually necessary
following all hematoma evacuation techniques
postoperatively for a short period.26 Unfortunately,
surgical evacuation does not hinder the underlying
process of inﬂammation and bleeding that is
responsible for the hematoma. As a result, the risk
of recurrence remains signiﬁcant.
In a meta-analysis of over 5400 procedures by
Ducret et al., the recurrence of chronic SDH was
estimated to be 11.7% for burr hole craniotomies,
19.4% for open craniotomies, and 28.1% for twist
drill craniotomies (Fig. 2).9 These procedures also
carry risks of complications. The same meta-analysis showed that the complication rates for these
procedures were 9.3%, 3.9%, and 2.5%, respectively.
Possible complications include intracerebral hematomas, seizures, and tension pneumocephalus.
Failure of cerebral re-expansion can also occur
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Fig. 1. Non-contrast CT head axial image showing mixed density of SDH overlying right cerebral hemisphere.

mainly due to the persistence of the dural membrane. Kung et al. established that the brain reexpanded only by about 41% on day 14 and by 60%
on day 30 while re-expansion was lesser in larger,
bilateral hematomas.24 Compared to unilateral
chronic SDH, bilateral chronic SDH resulted in
poorer brain re-expansion leading to brain parenchymal shift, damage to blood vessels, post-operative pneumocephalus, and cerebrospinal ﬂuid (CSF)
accumulation in the hematoma cavity, with subsequently higher recurrence rates.15,40,6
In light of the more recent understanding of the
pathogenesis of the disease, surgical procedures
have been modiﬁed keeping in mind the role out of
the outer dural membrane. In a meta-analysis of 17
clinical studies, Sahyouni et al. studied the effect of
combined craniotomy and membranectomy in
chronic SDH.39 They found that the mean recurrence rate was 7.6%. The morbidity rate, deﬁned as

a major complication, disability, or poor health, was
6.9%, and the mortality rate was 3.7%. Even though
the morbidity and mortality rates were comparable
to the standard surgical techniques, recurrence
rates were slightly lower with the addition of
membranectomy.
In an attempt to avoid surgical complications,
non-surgical modalities have been proposed.
Among these, steroids have been postulated as a
possible therapy as the belief is that their anti-inﬂammatory effects can decrease the size of the hematoma. They may also inhibit hematoma growth
by inhibiting vascular endothelial growth factor
(VEGF). Thotakura and Marabathina evaluated the
effect of steroids in 26 patients with chronic SDH.43
They found that 38.6% of patients did not show any
improvement. An additional 19% showed initial
improvement but developed recurrent symptoms
after three weeks. The authors concluded that
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Fig. 2. Comparison of the complications and risk of recurrence in 3 different surgical techniques used for hematoma evacuation.9

steroids appeared to be more successful in patients
with low-grade lesions.
Different treatment methods have also been
tested but with little beneﬁt. Atorvastatin can inhibit
inﬂammation and promote vascular maturation. In
one study, 25% of patients did not respond initially,
while 16.7% of patients who initially responded
required surgery later.5 Another retrospective study
evaluated the use of etizolam, a platelet-activating
factor receptor antagonist. It reduced the need for
surgery only in 46% of all patients.18 One systematic
review of all conservative management methods
concluded that they could be employed only in
small, unorganized lesions, where the neurological
status was stable.44

4. The basic anatomy of MMA (middle
meningeal artery)
The middle meningeal artery originates in the
infratemporal fossa, from the ﬁrst part of the internal maxillary artery. It enters the skull base at the
middle meningeal fossa, through the foramen spinosum. It divides into four branches from anterior

to posterior - the sphenoidal, frontal, parietal, and
petro-squamosal branches (Fig. 3).

5. Prospect of an alternative approach
It is the middle meningeal artery (MMA) that is
believed to feed the capillaries involved in the formation of chronic SDH. “Cotton wool-like staining’’
of the distal vasculature was seen on digital subtraction angiography (DSA).16 It also showed a
buildup of contrast, suggesting the fragility of newly
formed, immature blood vessels. Slow continuous
contrast injections created the appearance of
contrast outlining the hematoma. Contradictory to
the strictly venous pathology proposed traditionally,
other ﬁndings included direct arterial feeders.
Mino et al. evaluated four patients who presented
with recurrent chronic SDH following single burr
hole surgery.33 They performed super-selective
angiography of the MMA artery in these patients.
They found diffuse abnormal vascular stains around
the MMA, which, according to them, represented
the macro-capillaries on the external membrane of
the chronic SDH. Following MMA embolization, the
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Fig. 3. The middle meningeal artery entering the cranial vault through the foramen spinosum and dividing into its respective branches.

network of abnormal vasculature around the MMA
was no longer visible.

6. A lasting solution to a recurring problem
Initially, MMA embolization was used only when
surgical treatment had failed. 35Over time, surgeons
have used MMA embolization combined with surgery for refractory cases that do not respond to surgery alone. In these reports, while the surgical
evacuation relieves symptoms due to mass effect,
MMA embolization was utilized to prevent

recurrence by stopping a repeat of the chronic cycle
of re-accumulation. Okuma et al. demonstrated that
MMA embolization alone could also be effective in
cases of refractory chronic SDH.35 Seventeen patients
who underwent this procedure were followed for
over two years, with no signs of recurrence.
Improvement in neurological disability scores was
also seen, as measured by the modiﬁed Rankin scale
(mRS), after MMA embolization. Similarly, Shotar
et al. found that postsurgical embolization of the
MMA reduced the recurrence rate of chronic SDH
from 14% to 4%.41
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7. Testing MMA embolization as the sole
therapy
Recent studies show MMA embolization as the
only single therapy, has a role in select number of
cases. Link et al. prospectively followed 50 patients
who underwent MMA embolization for chronic
SDH. Of these, 42 patients underwent embolization
as ﬁrst-line treatment, and eight patients were
treated as recurrent cases after surgical evacuation
had failed.27 Four patients (8.9%) developed recurrence, and surgical evacuation had to be performed,
while 41 patients were stable and did not need
further intervention. In 31 of these latter patients,
imaging demonstrated a decrease in hematoma size
greater than 50%. In the same study, MMA embolization was used prophylactically after surgical
drainage in 10 patients. In a recent systematic review, Court et al. assessed 18 articles in which a total
of 190 patients had undergone MMA embolization.
The authors concluded that resolution occurred in
96.8% of all cases, with no post-procedure complications.7 A multicenter trial conducted by Kan et al.
involved 138 patients and 154 MMA embolization.
The study employed endovascular therapy as ﬁrstline treatment in patients with either mild symptoms or midline shift per CT of under 5 mm, and as
a secondary treatment in patients not meeting the
above criteria, which made up 66% of the total patients. 70.8% of patients had a greater than 50%
reduction in hematoma size, and only nine patients
(6.5%) required surgery. Hence, MMA embolization
can be considered a possibly safe and effective
alternative to conventional surgery for speciﬁc
patients.19
7.1. Is embolization superior to other management
options?
As of now, three studies have conclusively proven
that MMA is superior to other treatment modalities
for both initial and recurrent management. Ban
et al. compared conventional treatment modalities
with MMA embolization in 541 patients.3 Treatment
failure occurred in only 1.4% of patients who underwent MMA embolization. However, in patients
who underwent surgical removal, the failure rate
was 27.5%.
Kim compared MMA embolization against burr
hole craniotomy in patients with the prior surgical
evacuation of chronic SDH.21 They found that MMA
embolization was successful in all except one case
(3.8%), which eventually underwent spontaneous
regression. On the other hand, the recurrence rate
in patients who underwent craniotomy was 33.3%.

Repeat craniotomy was performed in 20.8% of patients, with craniotomy needed in 12.5%. As a result,
the author stated that MMA embolization must be
considered the preferred treatment in recurrent
chronic SDH.
In another comparative study, Matsumoto et al.
reviewed various options for managing recurrent
chronic SDH, deﬁned as two or more recurrent
episodes. Patients who underwent burr hole craniotomy alone had a recurrence rate of 25%.32 No
recurrence was seen in patients treated with MMA
embolization or craniotomy with outer membranectomy. The authors recommended that MMA
embolization should be considered for refractory
patients with small hematomas. However, for larger
organized hematomas, craniotomy with outer
membranectomy may be a more suitable option.
Based on the above studies and six other singlearm studies, Srivatsan et al. performed a metaanalysis to assess the efﬁcacy of MMA embolization.42 They found that the odds of developing a
recurrence after MMA embolization were 91.3% less
than conventional methods. The overall recurrence
rate was estimated to be 3.6%. Summary of the
studies included in the review are listed in Table 1.
7.2. Technical aspects of MMA embolization
MMA embolization is a minimally invasive procedure and can be performed under moderate
sedation or general endotracheal anesthesia. Arterial access is usually obtained through the common
femoral artery or the radial artery, with the latter
seen in more recent cases.37 The diagnostic catheter
is advanced to the common carotid artery (CCA).
The vascular source of the SDH should correspond
to the distribution of MMA. Under roadmap guidance, a microcatheter is advanced and carried
selectively into the MMA.28 Angiography of the
MMA helps to determine the branches of MMA that
supply the external membrane of chronic SDH.
Detailed knowledge of the anatomy of the external
carotid artery is of vital importance. MMA supplies
several cranial nerve nuclei, and its branches link
the external carotid and internal carotid arteries
through anastomoses. Therefore, it is imperative to
be aware of its branches before an embolization is
performed to prevent any serious adverse effects
and disabilities.
The MMA anastomoses with the anterior falcine
branch of the ophthalmic artery and the meningeal
branches of the cavernous branch of the internal
carotid artery (ICA). The cavernous branch (a
variant balanced through anastomoses with the
middle meningeal branch of the inferolateral trunk

Table 1. Summary of the studies included in the review.
Author

Study design

Criteria

Aim

Patient population

Conclusions

2018

No-nrandomized
clinical trial

Inclusion criteria: both genders,
aged 20 years or older with
chronic SDH
Exclusion criteria: chronic SDHs
with a focal location, thickness of
10 mm or less, no mass effect,
underlying conditions, poor
medical condition and with a life
expectancy of less than 6 months

To evaluate the effect of
MMA embolization on
chronic SDH and compare
the treatment outcomes of
MMA embolization and
conventional treatment

541 patients (391 male, 150
female) with chronic SDH
aged 20 years or older

Kim et al.41

2017

Pilot Study

Inclusion
criteria:
1)
not
requiring an emergent evacuation; 2) symptomatic recurrence
within a short time after successful treatment; 3) elderly with
brain atrophy; 4) enlarged ipsilateral MMA on magnetic resonance angiography (MRA); 5)
under antiplatelet and anticoagulant therapy; 6) advanced combined medical diseases; 7)
bleeding tendency or coagulopathy; and 8) hematomas with
multilocular collections

To describe the safety and
efﬁcacy of MMA embolization in recurrent chronic
SDHs

43 patients (30 male, 13
female) with one-time
recurrence of chronic
SDH, initially hospitalized
for burr-hole surgery to
evacuate unilateral or
bilateral chronic SDHs

Embolization group had a lower
treatment failure rate compared
to the conventional treatment
group (p ¼ .001), surgical rescue
was less frequent in the embolization group (p ¼ 0.005); however,
the
treatment
related
complication rate was similar
between
the
two
groups
(p ¼ 0.182)
MMA embolization was curative
with early brain re-expansion
(p ¼ 0.003) and a recurrence rate
of 3.8% compared to 33.3% in the
conventional treatment group
(p ¼ 0.024)

Ban et al.

Matsumoto et al.42

2018

Literature Review

Inclusion criteria: ipsilateral hematoma identiﬁed on follow up
computerized tomography (CT)
and causing neurological deﬁcits
withing 3 months of the last
operation
-Refractory was identiﬁed as
chronic SDH in patients presenting with recurrence on two
or more occasions

To
review
the
effective
surgical
procedures for refractory
chronic
SDH

14 (13 male, 1 female) patients with
refractory chronic
SDH
presenting
with two or more
recurrences

The cure rate was 100%
for both embolization of
the middle meningeal artery with burr-hole irrigation and drainage and
craniotomy, and 75% for
burr-hole irrigation and
drainage alone. No significant differences were
identiﬁed. No further recurrences were recorded.
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2020

Case series

Monocentric
retrospective study

Inclusion criteria: intractable risk
factors of chronic SDH included;
1) use of antiplatelet drugs or
anticoagulants, blood coagulation disorder 2) hepatic dysfunction 3) hemodialysis 4) terminal
malignancy 5) old age >80 years,
cerebral atrophy, large preoperative
hematoma
volume
(>150 mL) 6)niveau formation of
hematoma 7) conditions after
cerebrospinal ﬂuid shunt 8) no
placement of drain during surgery 9) postoperative residual air
(>20%) 10) multiple recurrences
Inclusion criteria: operated by a single burr hole
craniotomy for chronic
SDH recurrence or a
chronic SDH in the case of
an independent risk factor
deﬁned as: (1) antiplatelet
therapy or (2) full anticoagulation therapy or (3)
coagulation disorder or (4)
hepatopathy or (5) chronic
alcoholism
Exclusion criteria: eligible
patients were excluded if
they refused embolization
procedure or were denied
embolization
by
the
attending
physician
because they presented in
a moribund state, had
contraindication to embolization procedure like severe renal dysfunction, life
expectancy
below
6
months.

Reporting the usefulness of MMA
embolization
for
intractable chronic
SDH in patients
with
multiple
intractable
risk
factors

To assess the impact on
the recurrence rate of
post-surgical embolization
of chronic SDH in patients
with a higher than average
risk of recurrence

17 (12 male, 5 female) consecutive
patients with 2
intractable risk factors for chronic
SDH

The modiﬁed Rankin
Scale (mRS) score showed
signiﬁcant improvement
at the time of discharge
(p < 0.05) compared to
score at the time of
admission. MMA Embolization not associated with
recurrent chronic SDH or
rehospitalization in patients with intractable
chronic SDH

263 patients operated for a
chronic SDH (191 male, 72
female)

Post-surgical embolization
of the MMA reduced the
recurrence rate of chronic
SDH from 14% in the
control group to 4% in the
embolization
group
(p ¼ 0.002)
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Fig. 4. Digistal subtraction angiography (DSA) images of endovascular middle meningeal artery (MMA) embolization. A: Before embolization. B:
After embolization of frontal and parietal branches with polyvinyl alcohol (PVA) particles.

[ILT]) possibly supplying the Meckel cave and its
associated nerves. Since the MMA can connect with
the inferolateral trunk (ILT), it is also a possible
“dangerous anastomosis” with the ICA. An
extremely rare connection between the ILT and ICA
is possible through a very long route of the sphenoid branch connection to the recurrent meningeal
artery. Operators should also avoid the petrosal
branch of the MMA, and if a prominent branch is
identiﬁed, microcatheter is navigated past its takeoff, and reﬂux is avoided as this branch may be the
supply to vasa vasorum of cranial nerve VII within
the petrous bone, as well as the greater petrosal
nerve.
In addition, the microcatheter must be advanced
to the sphenoid ridge before the anastomotic junctions to avoid involving the meningo-ophthalmic
branches of the MMA.25 If embolization is performed too close to the anastomoses, there is a risk
of blindness or stroke. In case the vasculature is too
small to navigate distally, the procedure may not be
possible (Fig. 4).
7.3. Agents involved in MMA embolization
Studies conducted on MMA embolization have
mostly used polyvinyl alcohol (PVA) particles suspended in opaque carrier solution.30,3,28 However,
some authors have also used coils for embolization.48 Hashimoto et al. suggested that this approach

may be feasible when there is a likelihood of anastomosis with the ophthalmic artery in the proximal
part.16 However, Fiorella and Arthur suggested that
liquid embolic agents could be considered an
alternative, as they would be faster and simpler to
use.12 They pointed out that PVA particles can only
be viewed on the angiogram due to the opaque
carrier, making distal penetration and reﬂux difﬁcult to observe. However, since liquid agents are
inherently radio-opaque, visualization would be
easier and reﬂux better managed. Liquid agents like
cyanoacrylates and sodium tetradecyl sulfates have
been shown to produce better and more reliable
results; however, they can cause inﬂammatory reactions and even tissue death. Therefore, these factors must be evaluated thoroughly before such
agents are considered for MMA embolization.
Recently, Rajah et al. have successfully used both
non-adhesive (Onyx) and adhesive (cyanoacrylates)
liquids for MMA embolization in the management
of chronic SDH.37

8. Conclusions
MMA embolization is a promising treatment option for chronic SDH, in both primary and recurrent
cases. Although a few comparative studies have
proven its superiority, large-scale randomized
controlled trials with long follow-up periods are
essential to provide better evidence. Future research
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should also focus on evaluating different agents that
may be used for the embolization itself. Currently,
most of the chronic SDH patients present in the ED
for neurosurgical evaluation or are seen by primary
care physicians. Select patients must be made aware
of the option of endovascular therapy. The management of chronic SDH patients is complex and
includes observation, medical therapy, endovascular and surgical options. Therefore, one must be
cognizant of the need that successful implementation of this modality requires a whole-team
approach, as the role of MMA embolization in
treating chronic SDH will continue to evolve.

Authors’ disclosures and conﬂict of interest
Hamza Hanif: Nothing to disclose.
Shanza Farook: Nothing to disclose.
Sajid S. Suriya: Nothing to disclose.
Muhammad Umer Riaz Gondal: Nothing to
disclose.
Muhammad Ibraiz Bilal: Nothing to disclose.
Abu Baker Sheikh: Nothing to disclose.

References
1. Adhiyaman V, Asghar M, Ganeshram KN, Bhowmick BK.
Chronic subdural haematoma in the elderly. Postgrad Med.
2002;78(916):71e75.
2. Balser D, Farooq S, Mehmood T, Reyes M, Samadani U.
Actual and projected incidence rates for chronic subdural
hematomas in United States Veterans Administration and
civilian populations. J Neurosurg. 2015;123(5):1209e1215.
3. Ban SP, Hwang G, Byoun HS, et al. Middle meningeal artery
embolization for chronic subdural hematoma. Radiology. 2018;
286(3):992e999.
4. Barros S. The subdural space. Br J Anaesth. 1983;55(10):1043.
5. Chan DYC, Chan DTM, Sun TFD, Ng SCP, Wong GKC,
Poon WS. The use of atorvastatin for chronic subdural haematoma: a retrospective cohort comparison study. Br J Neurosurg. 2017;31(1):72e77.
6. Chen FM, Wang K, Xu KL, et al. Predictors of acute intracranial hemorrhage and recurrence of chronic subdural hematoma following burr hole drainage. BMC Neurol. 2020;20(1):
92.
7. Court J, Touchette CJ, Iorio-Morin C, Westwick HJ, Belzile F,
Effendi K. Embolization of the Middle meningeal artery in
chronic subdural hematoma - a systematic review. Clin Neurol
Neurosurg. 2019;186:105464.
8. D'Abbondanza JA, Loch Macdonald R. Experimental models
of chronic subdural hematoma. Neurol Res. 2014;36(2):
176e188.
9. Ducruet AF, Grobelny BT, Zacharia BE, et al. The surgical
management of chronic subdural hematoma. Neurosurg Rev.
2012;35(2):155e169. discussion 169.
10. Dumont TM, Rughani AI, Goeckes T, Tranmer BI. Chronic
subdural hematoma: a sentinel health event. World Neurosurg.
2013;80(6):889e892.
11. Edlmann E, Giorgi-Coll S, Whitﬁeld PC, Carpenter KLH,
Hutchinson PJ. Pathophysiology of chronic subdural haematoma: inﬂammation, angiogenesis and implications for pharmacotherapy. J Neuroinﬂammation. 2017;14(1):108.
12. Fiorella D, Arthur AS. Middle meningeal artery embolization
for the management of chronic subdural hematoma.
J Neurointerventional Surg. 2019;11(9):912e915.

13. Frontera JA, de los Reyes K, Gordon E, et al. Trend in
outcome and ﬁnancial impact of subdural hemorrhage. Neurocritical Care. 2011;14(2):260e266.
14. Gelabert-Gonz
alez M, Iglesias-Pais M, García-Allut A, Martínez-Rumbo R. Chronic subdural haematoma: surgical
treatment and outcome in 1000 cases. Clin Neurol Neurosurg.
2005;107(3):223e229.
15. Han M-H, Ryu JI, Kim CH, Kim JM, Cheong JH, Yi H-J.
Predictive factors for recurrence and clinical outcomes in
patients with chronic subdural hematoma. J Neurosurg. 2017;
127(5):1117e1125.
16. Hashimoto T, Ohashi T, Watanabe D, et al. Usefulness of
embolization of the middle meningeal artery for refractory
chronic subdural hematomas. Surg Neurol Int. 2013;4:104.
17. Hayakawa M. Pathophysiology of trauma-induced coagulopathy: disseminated intravascular coagulation with the
ﬁbrinolytic phenotype. J Inten Care. 2017;5:14.
18. Hirashima Y, Kurimoto M, Nagai S, Hori E, Origasa H,
Endo S. Effect of platelet-activating factor receptor antagonist,
etizolam, on resolution of chronic subdural hematoma–a
prospective study to investigate use as conservative therapy.
Neurol Med -Chir. 2005;45(12):621e626. discussion 626.
19. Kan P, Maragkos GA, Srivatsan A, et al. Middle meningeal
artery embolization for chronic subdural hematoma: a multicenter experience of 154 consecutive embolizations. Neurosurgery. 2021;88(2):268e277.
20. Katano H, Kamiya K, Mase M, Tanikawa M, Yamada K. Tissue plasminogen activator in chronic subdural hematomas as
a predictor of recurrence. J Neurosurg. 2006;104(1):79e84.
21. Kim E. Embolization therapy for refractory hemorrhage in
patients with chronic subdural hematomas. World Neurosurg.
2017;101:520e527.
22. Kim HC, Ko JH, Yoo DS, Lee S-K. Spontaneous resolution of
chronic subdural hematoma : close observation as a treatment
strategy. J Korean Neurosurg Soc. 2016;59(6):628e636.
23. Kolias AG, Chari A, Santarius T, Hutchinson PJ. Chronic
subdural haematoma: modern management and emerging
therapies. Nat Rev Neurol. 2014;10(10):570e578.
24. Kung W-M, Hung K-S, Chiu W-T, et al. Quantitative
assessment of impaired postevacuation brain re-expansion in
bilateral chronic subdural haematoma: possible mechanism
of the higher recurrence rate. Injury. 2012;43(5):598e602.
25. Larson A, Savastano L, Rammos S, Brinjikji W. Middle
meningeal artery embolization for chronic subdural hematoma: rationale, technique, and results. Contemp Neurosurg.
2020;42(9):1e6.
26. Lee S-J, Hwang S-C, Im SB. Twist-drill or burr hole craniostomy for draining chronic subdural hematomas: how to
choose it for chronic subdural hematoma drainage. Korean J
Nutr. 2016;12(2):107e111.
27. Link TW, Boddu S, Paine SM, Kamel H, Knopman J. Middle
meningeal artery embolization for chronic subdural hematoma: a series of 60 cases. Neurosurgery. 2019;85(6):801e807.
28. Link TW, Rapoport BI, Paine SM, Kamel H, Knopman J.
Middle meningeal artery embolization for chronic subdural
hematoma: endovascular technique and radiographic ﬁndings. Interv Neuroradiol: J Peritherap Neuroradiol Surg Proc Rel
Neurosci. 2018;24(4):455e462.
29. Mack J, Squier W, Eastman JT. Anatomy and development of
the meninges: implications for subdural collections and CSF
circulation. Pediatr Radiol. 2009;39(3):200e210.
30. Mandai S, Sakurai M, Matsumoto Y. Middle meningeal artery
embolization for refractory chronic subdural hematoma. Case
report. J Neurosurg. 2000;93(4):686e688.
31. Markwalder TM. Chronic subdural hematomas: a review.
J Neurosurg. 1981;54(5):637e645.
32. Matsumoto H, Hanayama H, Okada T, et al. Which surgical
procedure is effective for refractory chronic subdural hematoma? Analysis of our surgical procedures and literature review. J Clin Neurosci: Off J Neurosurg Soc Austr. 2018;49:40e47.
33. Mino M, Nishimura S, Hori E, et al. Efﬁcacy of middle
meningeal artery embolization in the treatment of refractory
chronic subdural hematoma. Surg Neurol Int. 2010;1:78.

34. Murakami H, Hirose Y, Sagoh M, et al. Why do chronic
subdural hematomas continue to grow slowly and not coagulate? Role of thrombomodulin in the mechanism.
J Neurosurg. 2002;96(5):877e884.
35. Okuma Y, Hirotsune N, Sato Y, Tanabe T, Muraoka K,
Nishino S. Midterm follow-up of patients with middle
meningeal artery embolization in intractable chronic subdural hematoma. World Neurosurg. 2019;126:e671ee678.
36. Potter JF, Fruin AH. Chronic subdural hematoma-the ‘great
imitator. Geriatrics. 1977;32(6):61e66.
37. Rajah GB, Tso MK, Dossani R, Vakharia K, Siddiqui AH.
Transradial embolization of the left middle meningeal artery
and accessory middle meningeal artery for treatment of
subacute-chronic subdural hematoma. J Neurointerventional
Surg. 2020;12(4):436.
38. Rauhala M, Luoto TM, Huhtala H, et al. The incidence of
chronic subdural hematomas from 1990 to 2015 in a deﬁned
Finnish population. J Neurosurg. 2019;132(4):1147e1157.
39. Sahyouni R, Mahboubi H, Tran P, Roufail JS, Chen JW.
Membranectomy in chronic subdural hematoma: meta-analysis. World Neurosurg. 2017;104:418e429.
40. Shen J, Gao Y, Li Q, et al. Risk factors predicting recurrence of
bilateral chronic subdural hematomas after initial bilateral
evacuation. World Neurosurg. 2019;130:e133ee139.
41. Shotar E, Meyblum L, Premat K, et al. Middle meningeal artery
embolization reduces the post-operative recurrence rate of at-

42.

43.
44.
45.

46.
47.
48.

35

risk chronic subdural hematoma. J Neurointerventional Surg.
2020;12(12):1209e1213.
Srivatsan A, Mohanty A, Nascimento FA, et al. Middle
meningeal artery embolization for chronic subdural hematoma: meta-analysis and systematic review. World Neurosurg.
2019;122:613e619.
Thotakura AK, Marabathina NR. Nonsurgical treatment of
chronic subdural hematoma with steroids. World Neurosurg.
2015;84(6):1968e1972.
Thotakura AK, Marabathina NR. The role of medical treatment in chronic subdural hematoma. Asian J Neurosurg. 2018;
13(4):976e983.
Tseng J-H, Tseng M-Y, Liu A-J, Lin W-H, Hu H-Y, Hsiao S-H.
Risk factors for chronic subdural hematoma after a minor
head injury in the elderly: a population-based study. BioMed
Res Int. 2014;2014:218646.
Uno M, Toi H, Hirai S. Chronic subdural hematoma in elderly
patients: is this disease benign? Neurol Med -Chir. 2017;57(8):
402e409.
Yadav YR, Parihar V, Namdev H, Bajaj J. Chronic subdural
hematoma. Asian J Neurosurg. 2016;11(4):330e342.
Yokoya S, Nishii S, Takezawa H, et al. Organized chronic
subdural hematoma treated with middle meningeal artery
embolization and small craniotomy: two case reports. Asian J
Neurosurg. 2020;15(2):421.

REVIEW ARTICLE

JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES 2022;12:25e35

